The University of Chicago Header Logo

Connection

George Bakris to Proteinuria

Back to Details
This is a "connection" page, showing publications George Bakris has written about Proteinuria.
George Bakris
Connection Strength
5.435
Proteinuria
  1. The current state of RAAS blockade in the treatment of hypertension and proteinuria. Curr Cardiol Rep. 2009 Nov; 11(6):436-42.
    View in: PubMed
    Score: 0.345
  2. Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? Curr Opin Nephrol Hypertens. 2009 Sep; 18(5):386-91.
    View in: PubMed
    Score: 0.341
  3. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008 Aug; 74(3):364-9.
    View in: PubMed
    Score: 0.312
  4. Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol. 2008 Jan; 3 Suppl 1:S3-10.
    View in: PubMed
    Score: 0.304
  5. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007 Jan; 49(1):12-26.
    View in: PubMed
    Score: 0.284
  6. Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial. J Hum Hypertens. 2006 Sep; 20(9):693-700.
    View in: PubMed
    Score: 0.272
  7. Proteinuria: a link to understanding changes in vascular compliance? Hypertension. 2005 Sep; 46(3):473-4.
    View in: PubMed
    Score: 0.258
  8. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005 Apr 25; 165(8):947-53.
    View in: PubMed
    Score: 0.252
  9. Is proteinuria a plausible target of therapy? Curr Hypertens Rep. 2004 Jun; 6(3):177-81.
    View in: PubMed
    Score: 0.237
  10. Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options. J Clin Hypertens (Greenwich). 2002 Jan-Feb; 4(1):52-7.
    View in: PubMed
    Score: 0.200
  11. Evolution of drugs that preserve renal function. J Clin Pharmacol. 2000 Sep; 40(9):978-89.
    View in: PubMed
    Score: 0.183
  12. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000 Sep; 36(3):646-61.
    View in: PubMed
    Score: 0.183
  13. Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019 12; 37(12):2307-2324.
    View in: PubMed
    Score: 0.173
  14. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998 Oct; 54(4):1283-9.
    View in: PubMed
    Score: 0.160
  15. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int. 1998 Sep; 54(3):889-96.
    View in: PubMed
    Score: 0.159
  16. Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens. 1997 Oct; 15(10):1181-5.
    View in: PubMed
    Score: 0.149
  17. The Kidney in Hypertension. Med Clin North Am. 2017 Jan; 101(1):207-217.
    View in: PubMed
    Score: 0.142
  18. Salt intake and reductions in arterial pressure and proteinuria. Is there a direct link? Am J Hypertens. 1996 Dec; 9(12 Pt 2):200S-206S.
    View in: PubMed
    Score: 0.141
  19. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int. 1993 Jun; 43(6):1210-8.
    View in: PubMed
    Score: 0.111
  20. Kidney dysfunction, cardiorespiratory fitness, and the risk of death in women. J Womens Health (Larchmt). 2012 Sep; 21(9):917-24.
    View in: PubMed
    Score: 0.102
  21. Blood pressure targets for patients with diabetes or kidney disease. Curr Hypertens Rep. 2011 Dec; 13(6):452-5.
    View in: PubMed
    Score: 0.100
  22. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med. 1990 Dec 15; 113(12):987-8.
    View in: PubMed
    Score: 0.093
  23. Dual RAAS blockade is desirable in kidney disease: con. Kidney Int. 2010 Sep; 78(6):546-9.
    View in: PubMed
    Score: 0.091
  24. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med. 1990 May 01; 112(9):707-8.
    View in: PubMed
    Score: 0.089
  25. The effects of enalapril on urinary protein excretion in patients with idiopathic membranous nephropathy. J Clin Pharmacol. 1990 Feb; 30(2):155-8.
    View in: PubMed
    Score: 0.088
  26. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009; 30(5):418-24.
    View in: PubMed
    Score: 0.085
  27. Effects of angiotensin II receptor blockers on diabetic nephropathy. J Hypertens Suppl. 2009 Jul; 27(5):S15-21.
    View in: PubMed
    Score: 0.084
  28. Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression. Postgrad Med. 2008 Apr; 120(1):33-42.
    View in: PubMed
    Score: 0.077
  29. Lessons learned from recent hypertension trials about kidney disease. Clin J Am Soc Nephrol. 2006 Mar; 1(2):229-35.
    View in: PubMed
    Score: 0.066
  30. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004 Jun; 65(6):1991-2002.
    View in: PubMed
    Score: 0.059
  31. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis. 2003 Oct; 42(4):617-22.
    View in: PubMed
    Score: 0.057
  32. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am J Hypertens. 1999 Aug; 12(8 Pt 2):80S-85S.
    View in: PubMed
    Score: 0.042
  33. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996 Nov; 50(5):1641-50.
    View in: PubMed
    Score: 0.035
  34. Diabetic nephropathy. What you need to know to preserve kidney function. Postgrad Med. 1993 Apr; 93(5):89-90, 93-5, 99-100.
    View in: PubMed
    Score: 0.027
  35. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int. 1992 Apr; 41(4):912-9.
    View in: PubMed
    Score: 0.025
  36. The effects of calcium antagonists on renal hemodynamics, urinary protein excretion, and glomerular morphology in diabetic states. J Am Soc Nephrol. 1991 Aug; 2(2 Suppl 1):S21-9.
    View in: PubMed
    Score: 0.024
  37. Renal effects of calcium antagonists in diabetes mellitus. An overview of studies in animal models and in humans. Am J Hypertens. 1991 Jul; 4(7 Pt 2):487S-493S.
    View in: PubMed
    Score: 0.024
  38. Assessment and management of vascular disease risk in patients with chronic kidney disease. J Clin Lipidol. 2011 Jul-Aug; 5(4):251-60.
    View in: PubMed
    Score: 0.024
  39. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20; 288(19):2421-31.
    View in: PubMed
    Score: 0.013
  40. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001 Jun 06; 285(21):2719-28.
    View in: PubMed
    Score: 0.012
  41. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int. 1999 May; 55(5):1849-60.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.